← Back to Clinical Trials
Recruiting NCT05058508

NCT05058508 LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05058508
Status Recruiting
Phase
Sponsor Wake Forest University Health Sciences
Condition Pediatric Cancer
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-03-11
Primary Completion 2027-11

Trial Parameters

Condition Pediatric Cancer
Sponsor Wake Forest University Health Sciences
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 2 Years
Max Age 25 Years
Start Date 2024-03-11
Completion 2027-11
Interventions
"Just Move" ExerciseStandard of Care Exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to see if there are physical and emotional benefits to participating in a structured exercise regimen for those who are ages 2-25, are newly diagnosed with a blood or solid tumor cancer, and are currently undergoing or will begin cancer treatment.

Eligibility Criteria

Inclusion Criteria: 1. Ages 2-25 at time of consent 2. Subject has newly diagnosed cancer per Investigator, and is planning to undergo chemotherapy for treatment of malignancy for at least 3 full cycles 3. Ability of subject (and/or parent/guardian) to read and understand the English or Spanish language 4. As determined and documented by the enrolling investigator, ability of the subject to understand and comply with study procedures for the entire length of the study 5. Subject has newly diagnosed cancer per Investigator and is planning to undergo chemotherapy, immunotherapy, or other systemically delivered for treatment of malignancy. Subjects are allowed to be enrolled up to 21 days after initiating cancer treatment. 6. Receiving oncologic care at Levine Children's Cancer and Blood Disorders Clinic. 7. Subject is anticipated to receive at least 3 full cycles of chemotherapy or other systemic cancer treatment. 8. Not participating in another clinical trial that precludes participatin

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology